AR107500A1 - Terapia de combinación de inhibidores de bromodominio y moduladores inmunitarios - Google Patents
Terapia de combinación de inhibidores de bromodominio y moduladores inmunitariosInfo
- Publication number
- AR107500A1 AR107500A1 ARP160103015A ARP160103015A AR107500A1 AR 107500 A1 AR107500 A1 AR 107500A1 AR P160103015 A ARP160103015 A AR P160103015A AR P160103015 A ARP160103015 A AR P160103015A AR 107500 A1 AR107500 A1 AR 107500A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- bromodomain inhibitor
- immune
- tautomer
- stereoisomer
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 6
- 238000002648 combination therapy Methods 0.000 title 1
- 229940125763 bromodomain inhibitor Drugs 0.000 abstract 11
- 239000013078 crystal Substances 0.000 abstract 7
- 229940002612 prodrug Drugs 0.000 abstract 7
- 239000000651 prodrug Substances 0.000 abstract 7
- 150000003839 salts Chemical class 0.000 abstract 7
- 239000012453 solvate Substances 0.000 abstract 7
- 101150051188 Adora2a gene Proteins 0.000 abstract 2
- -1 ICOS Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- LKEGXJXRNBALBV-PMCHYTPCSA-N 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-[4-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]butyl]acetamide Chemical group C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NCCCCNC(=O)COC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O LKEGXJXRNBALBV-PMCHYTPCSA-N 0.000 abstract 1
- VUVUVNZRUGEAHB-CYBMUJFWSA-N 7-(3,5-dimethyl-4-isoxazolyl)-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-3H-imidazo[4,5-c]quinolin-2-one Chemical group C1([C@@H](C)N2C3=C4C=C(C(=CC4=NC=C3NC2=O)C2=C(ON=C2C)C)OC)=CC=CC=N1 VUVUVNZRUGEAHB-CYBMUJFWSA-N 0.000 abstract 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 abstract 1
- 102100027207 CD27 antigen Human genes 0.000 abstract 1
- 102100038078 CD276 antigen Human genes 0.000 abstract 1
- 101710185679 CD276 antigen Proteins 0.000 abstract 1
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 102100025221 CD70 antigen Human genes 0.000 abstract 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 abstract 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 1
- 102100031351 Galectin-9 Human genes 0.000 abstract 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 abstract 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 abstract 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 abstract 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 abstract 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 abstract 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 abstract 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 abstract 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 abstract 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 abstract 1
- 102100034980 ICOS ligand Human genes 0.000 abstract 1
- 102000017578 LAG3 Human genes 0.000 abstract 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 abstract 1
- 102000004473 OX40 Ligand Human genes 0.000 abstract 1
- 108010042215 OX40 Ligand Proteins 0.000 abstract 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 abstract 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 abstract 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 abstract 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 abstract 1
- NETXMUIMUZJUTB-UHFFFAOYSA-N apabetalone Chemical group C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 NETXMUIMUZJUTB-UHFFFAOYSA-N 0.000 abstract 1
- QECMENZMDBOLDR-AWEZNQCLSA-N cpi 203 Chemical group N([C@@H](CC(N)=O)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 QECMENZMDBOLDR-AWEZNQCLSA-N 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236280P | 2015-10-02 | 2015-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107500A1 true AR107500A1 (es) | 2018-05-09 |
Family
ID=57137298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103015A AR107500A1 (es) | 2015-10-02 | 2016-09-30 | Terapia de combinación de inhibidores de bromodominio y moduladores inmunitarios |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190192532A1 (OSRAM) |
| EP (1) | EP3355922A2 (OSRAM) |
| JP (1) | JP2018530554A (OSRAM) |
| KR (1) | KR20180081507A (OSRAM) |
| CN (1) | CN108289957A (OSRAM) |
| AR (1) | AR107500A1 (OSRAM) |
| AU (1) | AU2016331190A1 (OSRAM) |
| BR (1) | BR112018006689A2 (OSRAM) |
| CA (1) | CA2999523A1 (OSRAM) |
| CL (1) | CL2018000853A1 (OSRAM) |
| HK (1) | HK1256269A1 (OSRAM) |
| IL (1) | IL258212A (OSRAM) |
| MA (1) | MA43037A (OSRAM) |
| MX (1) | MX2018003824A (OSRAM) |
| PE (1) | PE20181068A1 (OSRAM) |
| WO (1) | WO2017059319A2 (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3130350A1 (en) * | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| ES2820873T3 (es) | 2008-05-16 | 2021-04-22 | Taiga Biotechnologies Inc | Anticuerpos y su procesos de preparación |
| ES2681478T3 (es) | 2008-08-28 | 2018-09-13 | Taiga Biotechnologies, Inc. | Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC |
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| PL2571503T3 (pl) | 2010-05-14 | 2015-06-30 | Dana Farber Cancer Inst Inc | Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń |
| CA3133302A1 (en) | 2012-07-20 | 2014-01-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide |
| MX379463B (es) | 2013-11-08 | 2025-03-10 | Dana Farber Cancer Inst Inc | Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal. |
| JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス，インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
| EP3212654B1 (en) | 2014-10-27 | 2020-04-08 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
| KR20230091191A (ko) | 2016-05-27 | 2023-06-22 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| AU2017367730A1 (en) | 2016-12-02 | 2019-06-06 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11384069B2 (en) | 2018-01-16 | 2022-07-12 | Shenzhen Targetrx, Inc. | Diphenylaminopyrimidine compound for inhibiting kinase activity |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020051571A1 (en) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
| TWI816881B (zh) * | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 用於治療三陰性乳癌之組合療法 |
| EP3886904A4 (en) | 2018-11-30 | 2022-07-13 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| CN109666723B (zh) * | 2019-01-22 | 2022-04-15 | 南通大学 | 一种基于pdl1/pdl2超增强子的免疫检测点抑制剂的应用 |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| AU2020274117A1 (en) | 2019-05-14 | 2021-12-02 | Taiga Biotechnologies, Inc. | Compositions and methods for treating T cell exhaustion |
| US20230093080A1 (en) * | 2019-07-15 | 2023-03-23 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI867086B (zh) * | 2019-11-05 | 2024-12-21 | 加拿大商瑞斯弗洛吉克斯公司 | 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法 |
| JP7483032B2 (ja) * | 2019-11-26 | 2024-05-14 | ベノビオ カンパニー リミテッド | 新規ケルセチンレドックス誘導体及びｂｅｔ阻害剤としての用途 |
| TW202136251A (zh) | 2019-12-17 | 2021-10-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| RS66978B1 (sr) | 2020-07-02 | 2025-07-31 | Incyte Corp | Triciklična jedinjenja uree kao inhibitori jak2 v617f |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| US12171768B2 (en) | 2021-02-15 | 2024-12-24 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| JP2025504059A (ja) | 2022-01-31 | 2025-02-06 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋデグレーダー及びその使用 |
| KR20240163688A (ko) | 2022-03-17 | 2024-11-19 | 인사이트 코포레이션 | Jak2 v617f 억제제로서의 삼환계 우레아 화합물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012500894A1 (en) * | 2009-11-05 | 2022-03-09 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| CA2799381A1 (en) * | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
| PL2571503T3 (pl) * | 2010-05-14 | 2015-06-30 | Dana Farber Cancer Inst Inc | Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| WO2012075456A1 (en) * | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| JP2016513117A (ja) * | 2013-02-22 | 2016-05-12 | バイエル ファーマ アクチエンゲゼルシャフト | 過剰増殖性疾患を治療するためのｂｅｔタンパク質阻害剤としてのピロロ−およびピラゾロ−トリアゾロジアゼピン類 |
| WO2014128111A1 (de) * | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituierte pyrrolo- und pyrazolo-diazepine |
| BR112015023184A2 (pt) * | 2013-03-15 | 2017-11-21 | Constellation Pharmaceuticals Inc | método para o tratamento de uma doença, inibidor e seu uso, composição, método de identificação de um composto e método para inibir a produção de il-4, il-5 e il-13 |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| US20160158246A1 (en) * | 2013-08-06 | 2016-06-09 | Oncoethix Gmbh | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
| WO2015054642A2 (en) * | 2013-10-11 | 2015-04-16 | Genentech, Inc. | Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy |
| MX369491B (es) * | 2013-12-24 | 2019-11-11 | Bristol Myers Squibb Co | Compuestos tricíclicos como agentes anticancerígenos. |
-
2016
- 2016-09-30 KR KR1020187012018A patent/KR20180081507A/ko not_active Withdrawn
- 2016-09-30 BR BR112018006689A patent/BR112018006689A2/pt not_active IP Right Cessation
- 2016-09-30 MX MX2018003824A patent/MX2018003824A/es unknown
- 2016-09-30 AU AU2016331190A patent/AU2016331190A1/en not_active Abandoned
- 2016-09-30 US US15/764,131 patent/US20190192532A1/en not_active Abandoned
- 2016-09-30 PE PE2018000491A patent/PE20181068A1/es unknown
- 2016-09-30 JP JP2018517255A patent/JP2018530554A/ja active Pending
- 2016-09-30 CA CA2999523A patent/CA2999523A1/en not_active Abandoned
- 2016-09-30 HK HK18115329.0A patent/HK1256269A1/zh unknown
- 2016-09-30 WO PCT/US2016/054924 patent/WO2017059319A2/en not_active Ceased
- 2016-09-30 EP EP16781957.2A patent/EP3355922A2/en not_active Withdrawn
- 2016-09-30 AR ARP160103015A patent/AR107500A1/es unknown
- 2016-09-30 CN CN201680070462.8A patent/CN108289957A/zh active Pending
- 2016-09-30 MA MA043037A patent/MA43037A/fr unknown
-
2018
- 2018-03-19 IL IL258212A patent/IL258212A/en unknown
- 2018-04-02 CL CL2018000853A patent/CL2018000853A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108289957A (zh) | 2018-07-17 |
| WO2017059319A3 (en) | 2017-10-12 |
| MA43037A (fr) | 2018-08-08 |
| CL2018000853A1 (es) | 2018-08-31 |
| MX2018003824A (es) | 2019-04-01 |
| BR112018006689A2 (pt) | 2018-10-09 |
| KR20180081507A (ko) | 2018-07-16 |
| EP3355922A2 (en) | 2018-08-08 |
| CA2999523A1 (en) | 2017-04-06 |
| US20190192532A1 (en) | 2019-06-27 |
| JP2018530554A (ja) | 2018-10-18 |
| WO2017059319A2 (en) | 2017-04-06 |
| PE20181068A1 (es) | 2018-07-04 |
| IL258212A (en) | 2018-05-31 |
| AU2016331190A1 (en) | 2018-04-12 |
| HK1256269A1 (zh) | 2019-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107500A1 (es) | Terapia de combinación de inhibidores de bromodominio y moduladores inmunitarios | |
| CN110087730B (zh) | 使用包含parp抑制剂的组合产品治疗癌症 | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2018530554A5 (OSRAM) | ||
| US20230042913A1 (en) | A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf-kb ligand) antagonist for cancer therapy or prophylaxis and uses thereof | |
| JP2020514363A5 (OSRAM) | ||
| MY198034A (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| EP4157875A1 (en) | Antibodies to tigit | |
| EA034770B8 (ru) | Человеческие антитела к pd-1 | |
| CL2019003000A1 (es) | Proteínas de unión a antígenos trem2 y usos de estas. | |
| JP2024105268A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| CN111163798A (zh) | 用于抗lag-3抗体的给药方案及其用途 | |
| MX2020005894A (es) | Composicion combinada de un anticuerpo anti-pd-1 y lcl161 para el tratamiento de cancer. | |
| JP2019513725A5 (OSRAM) | ||
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| MX2009009636A (es) | Metodos para tratar enfermedades oftalmicas. | |
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| JP2019530431A5 (OSRAM) | ||
| HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
| AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
| HRP20192285T1 (hr) | Anti-ox40 protutijela i postupci uporabe | |
| JP2020502147A5 (OSRAM) | ||
| EP4286522A3 (en) | Fusion proteins of pd-1 and 4-1bb | |
| WO2019246593A3 (en) | Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |